Friday, July 30, 2010
York Pharma: date of interim results and trading update
Hitchin, UK, 9 April 2008 York Pharma, the AIM-listed (AIM:YRK) strategic acquirer, developer and marketer of pharmaceutical products in the field of dermatology, today confirms that it will announce its interim results for the half year ended 31 March 2008 on 28 May 2008 and provides an update on trading. This will be the first occasion that York Pharma's results will have been prepared under the recently introduced International Financial Reporting Standards ("IFRS").
Revenues for the period, including the contribution from Derms Development's products, which were acquired towards the end of 2007, are anticipated to be ahead of expectations as a result of strong growth in sales of all marketed products, notably Zindaclin ™, a treatment for mild to moderate acne. In addition, York Pharma's pipeline of innovative products continues to progress through its various stages of development.
Commenting on the update, Terry Sadler, CEO of York Pharma, said: "The integration of Derms Development has progressed well and we are now seeing the benefits of selling the brands through York's sales and distribution infrastructure in Europe. The roll-out of our business model continues to take shape as we build a specialist dermatology business with strongly growing marketed products and a piepline with high growth potential in all stages of development from pre-clinical through to Abasol ™, which awaits its first regulatory approval."
Published: 9th Apr 2008 - 08:25:33
Modified: 9th Apr 2008 - 08:42:53
